A detailed history of Alliancebernstein L.P. transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Alliancebernstein L.P. holds 1,734,821 shares of PCVX stock, worth $196 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares
1,734,821
Previous 1,780,703 2.58%
Holding current value
$196 Million
Previous $122 Million 7.69%
% of portfolio
0.05%
Previous 0.04%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$60.06 - $78.77 $2.76 Million - $3.61 Million
-45,882 Reduced 2.58%
1,734,821 $131 Million
Q1 2024

May 14, 2024

SELL
$59.79 - $81.05 $8.03 Million - $10.9 Million
-134,344 Reduced 7.02%
1,780,703 $122 Million
Q4 2023

Feb 14, 2024

SELL
$45.35 - $63.41 $1.31 Million - $1.83 Million
-28,783 Reduced 1.48%
1,915,047 $120 Million
Q3 2023

Nov 14, 2023

BUY
$46.0 - $53.1 $2.56 Million - $2.96 Million
55,724 Added 2.95%
1,943,830 $99.1 Million
Q2 2023

Aug 15, 2023

BUY
$34.66 - $54.07 $62.6 Million - $97.6 Million
1,804,718 Added 2164.24%
1,888,106 $94.3 Million
Q1 2023

May 15, 2023

BUY
$36.27 - $47.2 $351,819 - $457,840
9,700 Added 13.16%
83,388 $3.13 Million
Q4 2022

Feb 14, 2023

BUY
$20.58 - $47.95 $586,283 - $1.37 Million
28,488 Added 63.03%
73,688 $3.53 Million
Q2 2022

Aug 15, 2022

BUY
$17.68 - $26.58 $21,216 - $31,895
1,200 Added 2.73%
45,200 $984,000
Q1 2022

May 13, 2022

BUY
$17.46 - $26.36 $120,474 - $181,884
6,900 Added 18.6%
44,000 $1.06 Million
Q3 2021

Nov 10, 2021

BUY
$20.26 - $26.97 $139,794 - $186,093
6,900 Added 22.85%
37,100 $941,000
Q2 2021

Jul 30, 2021

BUY
$16.45 - $24.06 $128,310 - $187,668
7,800 Added 34.82%
30,200 $680,000
Q1 2021

May 06, 2021

SELL
$18.66 - $29.16 $74,640 - $116,640
-4,000 Reduced 15.15%
22,400 $442,000
Q3 2020

Nov 12, 2020

BUY
$26.5 - $55.4 $699,600 - $1.46 Million
26,400 New
26,400 $1.3 Million

Others Institutions Holding PCVX

About Vaxcyte, Inc.


  • Ticker PCVX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,315,100
  • Market Cap $6.71B
  • Description
  • Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...
More about PCVX
Track This Portfolio

Track Alliancebernstein L.P. Portfolio

Follow Alliancebernstein L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alliancebernstein L.P., based on Form 13F filings with the SEC.

News

Stay updated on Alliancebernstein L.P. with notifications on news.